Leading science, pioneering therapies
CRM Publications

Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.

TitleVascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.
Publication TypeJournal Article
Year of Publication1996
AuthorsVéniant M, Ménard J, Bruneval P, Morley S, Gonzales MF, Mullins JJ
JournalJ Clin Invest
Date Published1996 Nov 1
KeywordsAngiotensinogen, Animals, Animals, Genetically Modified, Base Sequence, Blood Pressure, Cardiovascular Diseases, Enzyme Precursors, Female, Gene Expression, Heart, Hypertension, Kidney, Liver, Male, Molecular Sequence Data, Organ Size, Rats, Rats, Inbred F344, Renin, Risk Factors, RNA, Messenger

We have developed a transgenic animal model to investigate the effects of overexpression of rat prorenin on the cardiovascular system. Two transgenic rat lines were generated in which rat prorenin expression was directed to the liver by a human alpha1-antitrypsin promoter. Liver-specific expression was confirmed by RNase protection assay. Plasma prorenin concentrations in transgenic rats were increased 400-fold in the males of both lines but were increased only two- to threefold in the females. Thus, transgene expression exhibited sexual dimorphism. Blood pressures were not significantly higher in transgenic rats than in nontransgenic controls. The ratio of heart weight to body weight was greater in male transgenic rats than in the nontransgenic controls. Histological analysis revealed severe renal lesions and hypertrophic cardiomyocytes in transgenic males only. This transgenic model demonstrates a likely role of prorenin in the development of cardiac and renal pathology independent of hypertension. These animals will facilitate studies of the effects of blockade of the renin-angiotensin system and other pharmacological interventions on the development and treatment of cardiac, vascular, and renal lesions induced by changes in this system in the absence of chronic hypertension.

Alternate JournalJ. Clin. Invest.
PubMed ID8903314
PubMed Central IDPMC507639